睿知中国疾病研究地图
候选清单0

即将招募B 细胞急性淋巴细胞白血病II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06861348,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 14 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. ECOG physical status score 0\~3, Karnofsky score ≥70;

    入选标准第 3 条

  3. Creatinine clearance rate≥50 mL/min (estimate by Cockcroft-Gault Equation);

    入选标准第 5 条

    Liver function: alanine transaminase (ALT) and aspartate aminotransferase (AST)≤ 3×upper limit of normal (ULN), and total bilirubin ≤ 2×ULN;

    入选标准第 6 条

  4. Women who are pregnant or breastfeeding, as well as those who are unwilling to take effective contraceptive measures;

    排除标准第 2 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06861348,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged 14-65 years, male or female;
  2. Participants with CD22 positive B-ALL/LBL who relapsed after allo-HSCT from a related or unrelated donor (regardless of CD22 expression);
  3. ECOG physical status score 0\~3, Karnofsky score ≥70;
  4. No active grade III/IV graft-versus-host disease (GvHD) or any active liver GvHD, no history of venous occlusive disease (VOD); No active GvHD and no previous history of VOD;
  5. Creatinine clearance rate≥50 mL/min (estimate by Cockcroft-Gault Equation);
  6. Liver function: alanine transaminase (ALT) and aspartate aminotransferase (AST)≤ 3×upper limit of normal (ULN), and total bilirubin ≤ 2×ULN;
  7. Left ventricular ejection fraction (LVEF) ≥50% as measured by echocardiography;
  8. Estimated life expectancy >3 months;
  9. Participants voluntarily participate in clinical trial; Understand and know this study, sign an informed consent form, and be willing to follow all experimental procedures.

排除标准:Exclusion Criteria:

  1. Allergic or with a history of serious adverse reactions to drugs or drugs with similar chemical structure in this study;
  2. Women who are pregnant or breastfeeding, as well as those who are unwilling to take effective contraceptive measures;
  3. Severe cardiac dysfunction: left ventricular ejection fraction (LVEF) <60%; Or severe arrhythmia: a history of a clinically significant corrected interval (QTc) prolongation (male >450ms; female>470 ms), ventricular tachycardia, atrial fibrillation, second degree atrioventricular block; myocardial infarction and coronary heart disease with clinical symptoms requiring medical treatment within one year before enrollment;
  4. Severe pulmonary disorders (obstructive or restrictive ventilation disorder);
  5. Severe liver function impairment: ALT, AST, or TBIL is more than 3 times higher than the upper limit of normal value (ULN);
  6. Severe renal impairment: serum Cr is more than 2 times higher than the upper limit of normal (ULN); Or 24-hour urinary creatinine clearance <50ml/min;
  7. Participants with active infection or active bleeding who were deemed intolerance to InO treatment by the investigators;
  8. A history of new thrombosis, embolism, cerebral hemorrhage or other diseases within one year before enrollment;
  9. Participants suffer from known or other mental disorders that investigators are unable to obtain informed consent and may interfere with their ability to comply with research requirements;
  10. A history of major organ surgery within the past six weeks;
  11. Drug abuse or chronic alcohol abuse that may affect the study results;
  12. Participants with a history of organ transplantation other than HSCT (except BMT);
  13. Other situations identified by the investigator as unsuitable to participate in the study.

引自 ClinicalTrials.gov, NCT06861348, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06861348,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06861348